Acronyms of Clinical Trial Names: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1,318: | Line 1,318: | ||
|- | |- | ||
| [[COOL MI]] | | [[COOL MI]] | ||
| [[Cooling As An Adjunctive Therapy To Percutaneous Intervention In Patients With Acute Myocardial Infarction]] | | [[Cooling As An Adjunctive Therapy To Percutaneous Intervention In Patients With Acute Myocardial Infarction]] | ||
|- | |- | ||
| Line 1,541: | Line 1,538: | ||
| [[DIG Enalapril]] | | [[DIG Enalapril]] | ||
| [[Enalapril Versus Digoxin In Patients With Congestive Heart Failure: A Multicenter Study (Canadian Enalapril Versus Digoxin Study Group)]] | | [[Enalapril Versus Digoxin In Patients With Congestive Heart Failure: A Multicenter Study (Canadian Enalapril Versus Digoxin Study Group)]] | ||
|- | |- | ||
| [[DIGAMI]] | | [[DIGAMI]] | ||
| Line 1,742: | Line 1,736: | ||
| [[ENABLE]] | | [[ENABLE]] | ||
| [[Effects Of The Endothelin Receptor Antagonist Bosentan On The Morbidity And Mortality In Patients With Chronic Heart Failure]] | | [[Effects Of The Endothelin Receptor Antagonist Bosentan On The Morbidity And Mortality In Patients With Chronic Heart Failure]] | ||
|- | |- | ||
| [[ENCOR]] | | [[ENCOR]] | ||
| [[Enrasentan Cooperative Randomized Evaluation]] | | [[Enrasentan Cooperative Randomized Evaluation]] | ||
|- | |- | ||
| [[ENCORE I]] | | [[ENCORE I]] | ||
| Line 1,762: | Line 1,750: | ||
|- | |- | ||
| [[ENDEAVOR III]] | | [[ENDEAVOR III]] | ||
| [[Randomized Comparison Of Zotarolimus-Eluting And Sirolimus-Eluting Stents In Patients With Coronary Artery Disease]] | | [[Randomized Comparison Of Zotarolimus-Eluting And Sirolimus-Eluting Stents In Patients With Coronary Artery Disease-3]] | ||
|- | |- | ||
| [[ENDEAVOR IV]] | | [[ENDEAVOR IV]] | ||
| [[Randomized Comparison Of Zotarolimus-Eluting And Paclitaxel-Eluting Stents In Patients With Coronary Artery Disease]] | | [[Randomized Comparison Of Zotarolimus-Eluting And Paclitaxel-Eluting Stents In Patients With Coronary Artery Disease-4]] | ||
|- | |- | ||
| [[ENDEAVOR-1]] | | [[ENDEAVOR-1]] | ||
| Line 1,775: | Line 1,763: | ||
| [[ENRICHD]] | | [[ENRICHD]] | ||
| [[Enhancing Recovery In Coronary Heart Disease]] | | [[Enhancing Recovery In Coronary Heart Disease]] | ||
|- | |- | ||
| [[ENTIRE]] | | [[ENTIRE]] | ||
| Line 1,790: | Line 1,775: | ||
| [[EPHESUS]] | | [[EPHESUS]] | ||
| [[Eplerenone Post-Ami Heart Failure Efficacy And Survival Study]] | | [[Eplerenone Post-Ami Heart Failure Efficacy And Survival Study]] | ||
|- | |- | ||
| [[EPIC]] | | [[EPIC]] | ||
| [[Evaluation Of C7E3 For The Prevention Of Ischemic Complications]] | | [[Evaluation Of C7E3 For The Prevention Of Ischemic Complications]] | ||
|- | |- | ||
| [[EPILOG]] | | [[EPILOG]] | ||
| [[Evaluation Of Ptca To Improve Long-Term Outcome By C7E3 Gp IIb/IIia Receptor (Abciximab) Blockade]] | | [[Evaluation Of Ptca To Improve Long-Term Outcome By C7E3 Gp IIb/IIia Receptor (Abciximab) Blockade]] | ||
|- | |- | ||
| [[EPISTENT]] | | [[EPISTENT]] | ||
Revision as of 21:13, 2 July 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
For other acronyms involved in clinical trials, click here
For detailed instructions on how to contribute to WikiDoc's Clinical Trials Wiki, click here